Dallas, TX, November 15, 2015 --(PR.com
)-- Biologics assist the natural process of bone formation. They can also be used as products that can cure the disease or degenerated discs. Biologics for the spine includes all the biological materials that play a role in a spinal procedure; these are one of the most innovative advances in spine surgical treatment. These are implants used in lieu allografts or as a support for bones in and around the spinal region.
Conventionally, allografts were considered as a gold standard for replenishment of the spinal bones. However, drawbacks such as donor site complications, high surgical cost, lengthy surgical procedures, and longer recovery time resulted in a shift from allograft bones to other biological alternatives, such as BMP, DBM, and bone substitutes. BMPs are proteins that are considered as essential in bone formation. They stimulate the process of bone growth and spinal fusion. They offer advantages such as minimal postoperative pain, shorter hospital stays, faster recovery, in addition to eliminating the need of harvesting bone from patient. Currently, clinical investigation in order to increase its application in spine degenerative disc surgery is in process. Another, common bone graft substitute is Demineralized Bone Matrix (DBM), derived from cadaver bone graft. They are available in various forms, such as putty, powder, gel, or chips. The global spine biologics market is expected to reach USD 2,459.3 million by 2020 at a CAGR of 4.4% from 2015 to 2020.
This growth in the market is driven by rising incidence of spinal disorders, rising healthcare expenditure in developing nations owing to growing income levels, rising obesity cases, awareness on the newly developed spine treatment techniques and devices, technological advancements, and rising demand of minimally invasive spine surgeries. However, the major restraints include scarcity of expertise, lack of patient awareness, and cost of surgery and reimbursement scenario.
The report – Global Spine Biologics market is analyzed and segmented on the basis of product, surgery type and geography. The product segment is categorized into bone grafts; bone graft substitutes; platelet-rich plasma (PRP) and bone marrow aspirate therapy among others. The surgery type segment is categorized into Anterior Cervical Discectomy and Fusion (ACDF); Transforamenal Lumbar Interbody Fusion (TLIF); Anterior Lumbar Interbody Fusion (ALIF); Lateral Lumbar Interbody Fusion (LLIF) among others.
On the basis of region, the global spine biologics market report studies major regions, such as North America, Europe, Asia-Pacific, and Rest of the World (RoW) North America contributed the largest share of 69.3% to the global spine biologics market, followed by Europe. The North American spine biologics market has witnessed significant growth in the recent years, as a result of the increased population, rise in awareness of newly developed technologies, increased per capita income, and improved medical literacy and tourism, among others. The increasing aging population and growing health concerns have led governments across the region to take several initiatives, thereby resulting in growth in the market.
The report also includes company share analysis for the major companies operating in this market by major regions North America, Europe and Asia Pacific. The details of mergers & acquisitions, product launches, expansions, and product life cycle matrix is also a part of this report. Some of the major players profiled in the in the global spine biologics market report include Arthrex, Inc. (U.S.), Cesca Therapeutics, Inc. (U.S.), Depuy Synthes, Inc. (U.S.), Dmp Spine (Greece), Exactech, Inc. (U.S.), K2m, Inc. (U.S.), Lattice Biologics (U.S.), Medtronic (Belgium), Nuo Therapeutics, Inc. (U.S.), Nutech (U.S.), Nuvasive, Inc. (U.S.), Orthofix Holdings, Inc. (U.S.), Regen Lab Sa, Rti Surgical, Inc., Stryker Corporation (U.S.), Wright Medical Technology, Inc. (Memphis, U.S.), X-Spine Systems, Inc. (U.S.), Zimmer Holdings, Inc. (U.S.), and others.
Data Bridge Market Research is providing a release offer to the first few clients a discount of 30% on this report, additionally 30 days of free customization is also included in this report. In case of requirement a presentation can also be bundled with this report including important graphs and charts. Procedure and patient data is also available though it may incur some additional charges.
For a free sample of this report please visit
Or Mail email@example.com